Highest-materiality recent filing
Elevance Health Q2 2026 EPS beats; raises full-year adjusted EPS guidance to at least $27.00
Operating revenue $49.8B (+0.8% YoY); diluted EPS $6.71, adjusted diluted EPS $7.45 (includes ~$0.80 net below-the-line benefit).
Elevance Health Q1 adj EPS $12.58 beats; raises FY2026 adj EPS guidance to at least $26.75
Q1 operating revenue $49.5B (+1.5% YoY); diluted EPS $8.00, adjusted diluted EPS $12.58 (includes ~$1 non-recurring investment income).
Elevance Health reaffirms FY2026 adj. EPS at least $25.50, benefit expense ratio ~90.2%
Reaffirms adjusted shareholders' earnings for FY2026 at least $25.50 per diluted share.
CMS notified Elevance of intent to impose sanctions suspending MA-PD enrollment and certain communications effective March 31, 2026 unless resolved.
CFO Mark Kaye adds Carelon oversight; Haytaian transitions; FY2026 guidance reaffirmed
Peter Haytaian steps down as Carelon President effective May 4, 2026; will serve as Special Advisor through Dec 31, 2026.
Q4 2025 GAAP diluted EPS $2.47; adjusted $3.33; operating revenue $49.3B (+10% YoY).
Q3 revenue $50.1B (+12% YoY), GAAP EPS $5.32, adj. EPS $6.03; FY guidance reaffirmed
Health Benefits operating revenue $42.2B (+10% YoY), operating margin 1.4%, medical membership ~45.4M.
Elevance Health closes $3B multi-tranche note offering; proceeds to refinance near-term debt
Issued $750M 4.000% notes due 2028, $750M 4.600% notes due 2032, $1,000M 5.000% notes due 2036, $500M 5.700% notes due 2055.
Elevance Health cuts FY2025 adjusted EPS guidance to ~$30 on elevated medical costs
Operating revenue $49.4B (+14.3% YoY); diluted EPS $7.72, adjusted diluted EPS $8.84.
Elevance Health Q1 2025 revenue $48.8B (+15.4% YoY); adj. diluted EPS $11.97; reaffirms FY guidance
Operating revenue $48.8B (+15.4% YoY); diluted GAAP EPS $9.61, adjusted diluted EPS $11.97.
Elevance Health pre-announces Q1 2025 adjusted EPS of $11.97; reaffirms FY guidance
Q1 GAAP EPS of $9.61, includes $2.36/share net unfavorable items; adjusted EPS $11.97.
Q4 operating revenue $45.0B (+6% YoY); FY revenue $175.2B (+3%).
Elevance Health closes $5.2B multi-tranche notes offering; proceeds for general corporate purposes
Issued $5.2B aggregate principal across six series: 2026 (4.500%), 2030 (4.750%), 2031 (4.950%), 2035 (5.200%), 2055 (5.700%), 2064 (5.850%).
Elevance Health Q3 adjusted EPS $8.37; FY2024 guidance cut to ~$33.00
Q3 2024 operating revenue $44.7B, up $2.2B YoY; diluted EPS $4.36 GAAP, adjusted $8.37.
Elevance Health Q2 diluted EPS $9.85 (+26% YoY); revenue $43.2B, down $0.2B
Adjusted diluted EPS $10.12 (+12% YoY); GAAP EPS at least $34.05 for FY2024, adjusted at least $37.20.
Elevance Health closes $2.6B senior notes offering in three tranches
Issued $600M 5.150% notes due 2029, $1B 5.375% notes due 2034, $1B 5.650% notes due 2054.
Elevance Health Q1 diluted EPS $9.59 (+15.5%); raises FY2024 adj. EPS guidance to >$37.20
Q1 operating revenue $42.3B (+0.9% YoY); diluted EPS $9.59 (+15.5%); adjusted diluted EPS $10.64 (+12.5%).
Reaffirms FY2024 EPS >$34.29; CMS Star update adds ~$190M benefit
Net income guidance >$34.29/sh, includes ~$2.81/sh unfavorable items; adjusted >$37.10/sh.
Elevance Health Q4 adj EPS $5.62 (+15.2% YoY); FY 2024 outlook above $37.10
Q4 GAAP diluted EPS $3.63 (+1.1% YoY); adjusted diluted EPS $5.62 (+15.2% YoY).
Elevance Health Q3 adj. EPS $8.99, revenue $42.5B (+7.2%); raises FY23 guidance
GAAP EPS $5.45 includes $3.54/share net negative items; adjusted EPS $8.99.
Elevance Health expects 2024 Medicare Star ratings drop: 34% in 4+ Star plans, vs 64% in 2023
Three largest Medicare Advantage contracts (~36% of members) fell to 3.5 Stars from 4 or 4.5 Stars.
Elevance Health names Mark Kaye new CFO to succeed retiring John Gallina; reaffirms 2023 guidance
Mark Kaye appointed EVP and CFO effective Nov 1, 2023; will serve as CFO Designate starting Sep 6.
Elevance Health Q2 GAAP EPS $7.79, adj. EPS $9.04; raises FY2023 guidance
Q2 GAAP net income $7.79/sh, adjusted $9.04/sh; operating revenue $43.4B (+12.7% YoY).
Elevance Health Q1 EPS $8.30 GAAP, $9.46 adjusted; raises full-year guidance
GAAP net income $8.30/share; adjusted net income $9.46/share, beating expectations.
Elevance Health issues $2.5B in three tranches of notes
Issued $500M 4.900% Notes due 2026, $1B 4.750% Notes due 2033, $1.1B 5.125% Notes due 2053.
GAAP EPS Q4 $3.93, FY $24.81; adjusted EPS Q4 $5.23, FY $29.07.
Elevance Health Q3 GAAP EPS $6.68, adj. $7.53; revenue up 11.5%; raises FY2022 outlook
GAAP net income $6.68/share vs $6.79 adjusted; adjusted EPS $7.53, up 10.9% YoY.
Elevance Health Q2 2022: Adj. EPS $8.04, revenue +15.6% to $38.5B; raises FY outlook
GAAP EPS $6.79; adjusted EPS $8.04, up 14.4% YoY.
On August 8, 2023, Elevance Health, Inc. (the “Company”) announced that Mark Kaye has been named Executive Vice President and Chief Financial Officer (“CFO”) of the Company, effective November 1, 2023 (the “Transition Date”).
Mr. Kaye succeeds John Gallina, who, after nearly thirty years of dedicated services to the Company, has decided to retire as CFO.
Elevance Health, Inc. (the “Company”) is today announcing that Gloria M. McCarthy will assume the new role of Special Advisor to the Chief Executive Officer and will no longer serve as Executive Vice President and Chief Administrative Officer of the Company, effective April 1, 2023.
On October 24, 2022, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Deanna Strable-Soethout to serve as an independent director effective November 1, 2022
On August 3, 2021, the Board of Directors (the “Board”) of the Company elected Susan Dodson DeVore to serve as an independent director effective immediately, with a term expiring at the Company’s 2022 annual meeting of shareholders.
Max materiality 0.85 · Median 0.60 · Most common event earnings